meitze
1 semana hace
Totally new ticker, new management, new everything. People already bashing it, lol. Maybe instead of being negative about it, we can get a little redemption for those who got scammed by Costello. However, grnf did pump to over $2 for a minute and many made bank on that scam. Perhaps we'll see $2 here one day.
bjl
2 semanas hace
MAJI: Ushering In A New Era With Transformative Biotech Acquisition
A significant transformation is underway for the OTC PINK listed $MAJI. The company is executing a high-profile acquisition of Exousia Pro, Inc. (EXO), a biotech venture at the forefront of next-generation medicine. With a new direction rooted in cutting-edge biotech, an imminent name change, and this transformative acquisition, MAJI is positioning itself to deliver what could be a breakthrough in modern healthcare.
At the heart of this transformation is EXO’s exclusive worldwide rights to patent-pending technology that utilizes exosomes – tiny, natural nanoparticles capable of delivering genetic material directly to diseased cells and tissues. This innovative platform, which harnesses both mammalian and plant-based exosomes, has the potential to address some of today’s most challenging health conditions, including cancer and cardiovascular diseases.
Why is this technology generating so much attention from researchers and clinicians? Exosomes act as the body’s natural delivery system, transporting genetic instructions and molecular cargo between cells. EXO’s proprietary advancements take this one step further by engineering exosomes to “carry” therapeutic molecules – such as DNA or mRNA – and deliver them precisely to their targets. By reducing off-target effects and improving delivery efficiency, this technology promises a level of precision that traditional treatments often lack.
This potential is grounded in the collaboration that brought it to life. EXO is a joint venture of Progenicyte Japan, a biotechnology firm renowned for its work in genetic engineering, regenerative medicine, and advanced drug delivery systems. Progenicyte Japan’s collaborations with the University of Florida and Kyoto University bring world-class academic expertise and intellectual resources to EXO’s mission. Together, they are pushing the boundaries of what exosome technology can achieve – not just in oncology, but also in areas such as Alzheimer’s disease and Down syndrome.
Marijuana Inc
The acquisition is further bolstered by the company’s efforts to set the stage for success in its new era. Plans to pursue SEC reporting status and adopt a leaner share structure – from 750 million authorized shares down to 250 million – demonstrate a commitment to transparency and a more shareholder-friendly framework. Updates on the OTC Markets platform are already in progress, and the company has announced plans for a name change and a new website launch set for January 1, 2025.
This transformation is unfolding at a time when the healthcare industry is eager for breakthrough solutions. Many existing treatments struggle to deliver therapeutic agents precisely where they are needed, leading to limited efficacy and unwanted side effects. EXO’s exosome-based approach offers a highly tailored solution, potentially overcoming these challenges. For example, the company has indicated interest in glioblastoma, a particularly aggressive form of brain cancer, where targeted therapies could offer new hope for patients.
With its new brand set to launch on January 1, 2025, MAJI is ready to step into the biotech space with purpose. The acquisition of EXO brings advanced exosome technology to the forefront, positioning the company to address some of medicine’s toughest challenges, including cancer, Alzheimer’s, and glioblastoma. This launch represents a key moment in MAJI’s transformation and potentially a major step forward for modern healthcare.
*This article has been cross-published from DegenMag.com; See all disclosures and disclaimers here
https://x.com/DegenMagazine/status/1868558821729149089
bjl
2 semanas hace
Business Description
Exousia Pro, Inc. (EXO) Is a joint venture with the Japanese biotech company Progenicyte Japan Co., ltd. (PJC) to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells. EXO has an exclusive worldwide license of this patent pending technology, and its goal is to become a leader in the manufacture and delivery of mammalian and plant based therapeutic exosomes. Under the license agreement and filed patents, EXO will be the only company capable of producing and providing loaded exosomes. EXO has developed proprietary technology that allows custom production of exosomes with enhanced genetic function that can target certain cells, tissues or organs. The company can modify the exosomes to contain the desired payload of molecules to perform needed healing functions within diseased or cancerous cells or tissues. The mission of the company is to provide genetically contained exosomes in unserved global healthcare needs such as cancer and cardiovascular diseases. The manipulation of genes at a cellular level holds the key to attacking incurable diseases such as cancer and to treat diseases that do not respond to current drug therapy. The main problem confronting pharmaceutical companies lies in the ability to deliver effective targeted genetic therapy to tissues and cells. EXOs patent pending technology has the potential answer.
https://www.otcmarkets.com/stock/MAJI/profile
Potse
3 semanas hace
MAJI(.0349)...Exousia/Progenicyte possible acquisition targets......
The potential upside here could be pretty good, depending on how everything gets structured. One thing that does seem somewhat strange to me is the timing of the name/symbol change and potential acquisition of a biotech company. It is not clear yet whether the new incoming biotech will become the primary focus of MAJI going forward, with the marijuana-related business seeing a less prominent role or perhaps even a divesture of that business. Unless the incoming biotech is closely associated with the cannabis industry, I would think the new company would prefer another completely different name/symbol. Maybe the possibility of this new incoming company did not materialize until the name/symbol change was so far into the FINRA processing that they decided to just allow it to proceed.
Based on the limited information out there right now, my guess is that Exousia AI and/or Progenicyte could be the most likely acquisition targets. Progenicyte is involved in a lot of areas of biotech research/development, so I am not sure if MAJI would acquire the entire company, some type of spinoff from Progenicyte, or just license some of its technology.
Reason why I think those two companies seem like the logical targets: Prior to Mike Sheikh taking control of MAJI, the company had posted a tweet stating that the incoming biotech company was involved with a revolutionary drug delivery system. The tweet specifically mentioned the platform's use on glioblastoma (brain cancer). Sheikh does investor relations work for LUDG, which has a subsidiary called "Exousia AI". Exousia is involved in an exosomal delivery platform and just happens to be involved with a brain cancer study being conducted by Kiminobu SugayaI (Progenicyte). I find it rather interesting that Sheikh's email contact information on the MAJI OTC profile contains the word "exousia". As far as I am aware he does not use that particular email on any other company he is associated with. I suppose this "exousia" connection here could be nothing more than a coincidence, but it would certainly seem like an extremely strange coincidence.
Could be completely wrong with my guess, but this seems like the most logical scenario that I can think of at the moment. LUDG's 3/27/2024 press release has information regarding Exousia AI and the brain cancer study. I've placed some things of interest in bold.......
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. The study is being done in the lab of Dr. Kiminobu Sugaya PhD, Head of Neuroscience, Burnett School of Biomedical Sciences, University of Central florida, Orlando, Florida. Dr. Sugaya and his research team are developing a more effective way to treat GBM, an aggressive, incurable form of brain cancer.
GBM accounts for 48% of all primary malignant brain tumors and is by far the most aggressive brain cancer with an average lifespan of 12-14 months after diagnosis, if not treated. This devastating brain cancer does not distinguish between people, young or old. Well known individuals who have died of GBM include, Beau Biden, John McCain and Ted Kennedy.
New research led by Dr. Sugaya, a stem cell researcher and neuroscientist, found that targeting a drug resistant mechanism in cancer stem cells significantly enhanced the efficacy of traditional cancer therapies - making them four times more effective against GBM. Current FDA-approved drugs kill less than 25% of glioblastoma cancer stem cells (CSCs). The study sponsored by Exousia AI will employ this unique strategy and potentially increase the efficacy of Merck’s FDA approved drug Temozolomide in the treatment of GBM by 400%.
Marvin S. Hausman MD, CEO, stated: “I have thoroughly analyzed Dr. Sugaya’s exosome-based targeted drug delivery system many times, and the potential that this breakthrough technology offers. We are embarking on a revolutionary new development in medicine.”
About UCF Glioblastoma Study:
https://www.ucf.edu/news/ucf-researchers-develop-novel-therapy-for-incurable-brain-cancer/
About Ludwig Enterprises, Inc.:
Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor and create solutions to prevent chronic inflammation, the causative agent of illnesses which are responsible for more than 50% of deaths worldwide. Exousia AI, a subsidiary has created an Exosomal Targeted Delivery Platform. This transformational technology will lead to the creation of new therapeutics and improve the efficacy of existing treatments.
https://www.otcmarkets.com/stock/LUDG/news/Ludwig-Enterprises-Inc-OTCLUDG-Funds-Incurable-Brain-Cancer-Study?id=434885
https://www.ucf.edu/news/ucf-researchers-develop-novel-therapy-for-incurable-brain-cancer/
https://www.linkedin.com/in/kiminobu-sugaya/
https://progenicytetherapeuticsinc.com/
https://www.progenicytejapan.com/exosomes/
136
1 mes hace
otc markets page updated $MAJI MAJI
Mike now shown as ceo
also new company insider with affiliation w/ mushrooms inc
Kimberly Carlson
has patent https://patents.justia.com/inventor/kimberly-zawi-carlson
Abstract: A method of generating multifunctional mycelium products (thread, foam, films, gels and liquids) derived from biodegraded waste and fungi includes inoculating a carbon-containing substrate with fungi; growing the fungi to form a mature mycelium; separating the mycelium from the carbon-containing substrate; and drying the mature mycelium. The mycelium is either injected into a mold and expanded, fermented to produce a liquid, or blended with water and gelling agents to form a hydrogel. The products sequester carbon and inherently combat pathogens, notably MRSA. Further augmented with synthetic enzyme substrates, the products offer bacterial detection. A standout feature is their capacity to hold and release therapeutic agents, diversifying their use from sustainable textiles to skincare, wound healing, and precise drug delivery.
Type: Application
Filed: October 17, 2023
Publication date: July 25, 2024
Applicant: Mushrooms Inc.
Inventors: Kimberly Zawi Carlson, Donald Steinberg, Hyder Ali Khoja, Maqsad Suriev
Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
uber darthium
1 semana hace
strippa
2 semanas hace
Hot Features
Premium
